Diuretic Efficacy of Dexamethasone in Heart Failure
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether glucocorticoids have potent diuretic effects in patients with congestive heart failure.
| Condition | Intervention | Phase |
|---|---|---|
|
Heart Failure, Congestive |
Drug: dexamethasone |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Diuretic Efficacy of Dexamethasone in Congestive Heart Failure Patients |
- urine volume
- urine electrolyte excretion (urine sodium, urine potassium, urine chloride), and urine creatinine.
- serum electrolyte (serum sodium, serum potassium, serum chloride), serum creatinine, serum urea, serum uric Acid.
- fractional sodium excretion
- glomerular filtration rate (calculated by Cockroft and Gault formula).
| Estimated Enrollment: | 60 |
| Study Start Date: | March 2006 |
| Estimated Study Completion Date: | December 2006 |
Glucocorticoids are known to have pronounced physiological effects in the kidney. Conventional teaching dictates that it should be used with caution in patients with congestive heart failure due to its fluid and sodium retention effects. Surprisingly, despite the widespread prevalence of this belief within the medical community, there are few data to support it. In fact, several small animal studies have documented its striking diuretic effects due to increased renal plasma flow and glomerular filtration rate without changes in the glomerular filtration fraction. We design this study to determine whether glucocorticoids have a potent diuretic effect in patients with heart failure.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Congestive heart failure patients due to any cause
- Patients with normal cortical function
- Congestive heart failure patients who are on diuretic therapy
- Clinically stable and body weight maintained the same for at least 3 days without signs of fluid retention
Exclusion Criteria:
- Patient refusal
- Signs of infection
Contacts and Locations| China, Hebei | |
| Kunshen Liu | |
| Shijiazhuang, Hebei, China, 050031 | |
| The First Hospital of Hebei Medical University | |
| Shijiazhuang, Hebei, China, 050031 | |
| Study Chair: | Kunshen Liu, M.D. | Hebei Medical University |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00263302 History of Changes |
| Other Study ID Numbers: | 0512-e |
| Study First Received: | December 7, 2005 |
| Last Updated: | July 2, 2008 |
| Health Authority: | China: Food and Drug Administration |
Keywords provided by Hebei Medical University:
|
dexamethasone, diuretic, congestive heart failure |
Additional relevant MeSH terms:
|
Heart Failure Heart Diseases Cardiovascular Diseases Dexamethasone acetate Dexamethasone Dexamethasone 21-phosphate BB 1101 Diuretics Anti-Inflammatory Agents Therapeutic Uses Pharmacologic Actions Antiemetics Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Central Nervous System Agents Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Natriuretic Agents |
ClinicalTrials.gov processed this record on May 16, 2013